FDA Approves Otezla for Treatment of Oral Ulcers Associated with Behçet’s Disease Approvals, Behcet's Disease Uveitis, Clinical Studies, FDA, FDA/Regulatory, New Indications, Oral Ulcers, PDE4 Inhibitors The U.S. Food and Drug Administration approved Celgene Corp.’s Otezla (apremilast) 30 mg twice daily for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. Read more July 19, 2019/by Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Business Wire2019-07-19 13:59:492019-07-25 11:44:50FDA Approves Otezla for Treatment of Oral Ulcers Associated with Behçet’s Disease
